Pre Application for the 2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders (X02) | Apply Online

Opportunity Summary:

This grant opportunity, titled "Pre-Application for the 2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders (X02)" (Funding Opportunity Number PAR-11-269), is a National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) announcement aimed specifically at soliciting pre-applications rather than full proposals. The core intent is to identify and encourage strong prospective candidates for the NIDA Translational Avant Garde Award, a program built to back highly capable basic and/or clinical researchers who have the creativity, expertise, and long-term commitment needed to move promising scientific discoveries toward real-world medications for substance use disorders (SUDs). In practical terms, the focus is on translation: taking ideas, mechanisms, targets, compounds, biomarkers, or clinical insights that may exist at an early or mid-stage and pushing them along the path toward safe and effective treatments that can be used in clinical settings.

NIDA frames this effort as part of a broader commitment to accelerate progress in medication development for SUDs, emphasizing substances that represent major public health burdens and for which better pharmacologic treatment options are needed. The announcement explicitly includes SUDs related to tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioid use or misuse. The underlying message is that NIDA is looking for researchers who are not only scientifically strong, but who also have a clear translational vision and the practical drive to navigate the difficult steps between discovery and an approved or clinically viable medication candidate. While the text provided does not lay out specific scientific requirements or review criteria, the name and stated purpose make it clear the pre-application is meant to surface investigators and project concepts with genuine medication-development potential, rather than purely descriptive or basic research with no path toward therapeutic translation.

Administratively, this is a discretionary grant opportunity using the grant funding instrument, and it falls under the activity area broadly associated with education and health. The associated CFDA listing is 93.279, Drug Abuse and Addiction Research Programs, which signals it sits within NIH/NIDA's established research funding portfolio in substance use and addiction science. The opportunity does not require cost sharing or matching funds, reducing a common barrier for applicants and making it more accessible to organizations that might not have flexible institutional resources to commit up front.

Eligibility is intentionally broad and includes a wide range of institution types. Eligible applicants include nonprofit organizations both with and without 501(c)(3) status (with the noted exception language for certain categories), public and private institutions of higher education, public and state-controlled universities, for-profit organizations other than small businesses, and small businesses. Governmental entities at multiple levels are also eligible, including state governments, county governments, city or township governments, special district governments, and independent school districts, along with public housing authorities and Indian housing authorities. The eligibility list also explicitly extends to federally recognized Native American tribal governments and tribal organizations that are not federally recognized, as well as regional organizations and tribally controlled colleges and universities.

The announcement further clarifies inclusion of institutions and organizations that NIH commonly highlights to broaden participation and support diverse research ecosystems. These include Alaska Native and Native Hawaiian Serving Institutions, Hispanic-Serving Institutions, Historically Black Colleges and Universities (HBCUs), and other faith-based or community-based organizations, along with eligible federal government agencies. Importantly, the FOA states that foreign institutions (non-U.S. entities) are eligible to apply, and that non-U.S. components of U.S. organizations may also apply. That detail matters because it signals NIDA is open to global expertise and cross-border collaborations when they meaningfully advance medication development for SUDs.

In terms of timing, the opportunity was posted and created on July 29, 2011. The original and current closing date listed is October 20, 2011, with an archive date of November 20, 2011. Those dates place the FOA firmly in the 2012 award cycle context and also indicate the window for submitting the pre-application was relatively short, which is common for pre-application solicitations meant to quickly identify a pool of strong candidates for a more selective subsequent stage.

For applicants seeking the official details, NIH provided an additional information link to the full FOA on the NIH grants guide website. The contact information included is primarily technical and access-related, directing users who have trouble accessing the announcement or linking to it to the NIH Office of Extramural Research (OER) webmaster email. Overall, the opportunity can be understood as an entry step into a high-impact, investigator-focused NIDA program designed to speed the movement of addiction science discoveries into tangible medications for major substance use disorders, using a pre-application process to efficiently identify the most compelling investigators and translational concepts for further consideration.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Pre Application for the FY12 NIDA Avant Garde Award Program for HIV/AIDS Research (X02)

Previous opportunity: 2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 11 269

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 11 269) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 269", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.